临床护理路径在紫杉醇联合卡铂治疗卵巢癌护理中的应用及对患者QOL评分的影响

Application of Clinical Nursing Path in Paclitaxel Combined with Carboplatin in the Nursing Care of Ovarian Cancer and Its Influence on Patients'QOL Score

目的探讨对卵巢癌患者在紫杉醇联合卡铂治疗期间采用临床护理路径干预的效果及对改善患者QOL评分的作用。方法随机选择该院2020年1—12月收治的卵巢癌患者80例,按照随机数表法分为两组,对照组(n=40)采用常规健康教育、心理护理方案;研究组(n=40)则在对照组的基础上采用临床护理路径干预,比较两组患者入院时与出院前的汉密尔顿焦虑(HAMA)、抑郁(HAMD)量表评分以及生存质量测定量表(QOL)评分,并采用自制满意度调查问卷调查两组患者对护理服务的满意度。结果出院前,研究组HAMA、HAMD评分分别为(12.25±3.02)分、(14.07±3.55)分,均低于对照组,生理健康、心理健康、社会关系、周围环境评分分别为(17.40±2.87)分、(16.91±1.85)分、(19.24±2.63)分、(20.65±3.42)分,均高于对照组,差异有统计学意义(t=3.626、4.157、4.232、3.204、7.209、3.293,P<0.05)。研究组满意度为97.50%,高于对照组的80.00%,差异有统计学意义(χ^(2)=4.507,P<0.05)。结论对卵巢癌患者在紫杉醇联合卡铂治疗的基础上通过实施临床护理路径方案可改善卵巢癌患者化疗期间的不良情绪以及生活质量,有利于改善护患关系,值得推广。

Objective To investigate the effect of clinical nursing pathway intervention on patients with ovarian cancer during the treatment of paclitaxel combined with carboplatin and the effect on improving the QOL score of patients.Methods A total of 80 ovarian cancer patients admitted to the hospital from January to December 2020 were randomly selected,and they were divided into two groups according to the random number table method.The control group(n=40)adopted routine health education and psychological care programs.The study group(n=40)used clinical care pathway intervention on the basis of the control group to compare the hamilton anxiety(HAMA)and depression(HAMD)scale scores and the quality of life measurement scale(QOL)score,and a self-made satisfaction survey questionnaire was used to investigate the satisfaction of the two groups of patients with nursing services.Results Before discharge,the HAMA and HAMD scores of the study group were(12.25±3.02)points and(14.07±3.55)points,respectively,which were lower than those of the control group;the scores of the study group of physical health,mental health,social relations,and surrounding environment were(17.40±2.87)points,(16.91±1.85)points,(19.24±2.63)points,and(20.65±3.42)points,respectively,were higher than the control group,the difference was statistically significant(t=3.626,4.157,4.232,3.204,7.209,3.293,P<0.05).The satisfaction degree of the study group was 97.50%,which was higher than 80.00%of the control group,and the difference was statistically significant(χ^(2)=4.507,P<0.05).Conclusion For patients with ovarian cancer,on the basis of paclitaxel combined with carboplatin therapy,the implementation of clinical care pathway programs can improve the bad mood and quality of life of patients with ovarian cancer during chemotherapy,which is beneficial to improve the nurse-patient relationship and is worthy of promotion.